F109 Side Effects May Include: Illustrative Cases of Dermatologic Adverse Events
DESCRIPTION
Dermatologists are frequently called upon to diagnose and manage patients with suspected drug rashes. With the pace of new medication development, it is important but difficult to keep up with the spectrum of side effects relevant to dermatology. This case-based interactive session will explore dermatologic adverse events. This will include cutaneous adverse reactions of non-dermatologic medications, as well as rare potential side effects of medications commonly prescribed by dermatologists. Cases will be selected that illustrate the clinical presentation, differential diagnosis, workup, and management of a variety of cutaneous adverse reactions and dermatologic drug side effects. This activity has been approved by the American Board of Dermatology (ABD) for up to 20 Continuous Certification Program (CCP) Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org.
LEARNING OBJECTIVES
Recognize different forms of cutaneous adverse reactions and uncommon side effects of dermatologic medications.
Manage patients with dermatologic adverse reactions and develop evaluation and treatment plans based on reaction type.
Determine the most likely causative medications for specific cutaneous adverse reactions.
SCHEDULE
1:00 PM
Medication Side Effects in Children
Andrea Waldman, MD, FAAD
1:30 PM
Medication Safety in Older Adults
Daniel Charles Butler, MD, FAAD
2:00 PM
Side Effects May Include...
Cindy Owen, MD, FAAD
2:30 PM
Side Effects in Skin Cancer Patients
Margaret (Molly) Moye, MD, FAAD
DIRECTOR
Margaret (Molly) Moye, MD, FAAD
SPEAKERS
Daniel Charles Butler, MD, FAAD
Cindy Owen, MD, FAAD
Andrea Waldman, MD, FAAD
DISCLOSURES
Daniel Charles Butler, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Dermira/Lilly – Speaker(Honoraria); Galderma – Advisory Board(Fees); Leo Pharma Inc – Advisory Board(Fees); Novartis – Advisory Board(Honoraria), Speaker(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Speaker(Honoraria);
Margaret (Molly) Moye, MD, FAAD
Forefront Dermatology – Advisory Board(Stock Options), Employee (w-2 relationship)(Salary), Stockholder(Stock);
Cindy Owen, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Alumis – Investigator(Grants/Research Funding); Amgen – Investigator(Grants/Research Funding); Bluefin – Investigator(Grants/Research Funding); Eli Lilly and Company – Investigator(Grants/Research Funding); Galderma – Investigator(Grants/Research Funding); Incyte – Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Nektar Therapeutics – Investigator(Grants/Research Funding); Novartis – Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); Sanofi – Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding); Teva Pharmaceutical Industries Ltd. – Investigator(Grants/Research Funding); Veradermics – Investigator(Grants/Research Funding); Zura Bio – Investigator(Grants/Research Funding);
Andrea Waldman, MD, FAAD
No financial relationships exist with ineligible companies.